For over 30 years, MedWorks Media has been bridging research and clinical practice as a psychiatric medical publisher.
This issue features systematic reviews and meta-analyses on centanafadine for ADHD and deutetrabenazine for Tourette syndrome, original research on GH001 in treatment-resistant depression and inflammation-based predictors of PTSD treatment response, a clinical update on evidence-based pharmacotherapies for major depressive disorder, review articles on eugeroics and antipsychotic-associated cardiotoxicity beyond clozapine, and case reports spanning ECT with ketamine in bipolar depression, agomelatine for adolescent bipolar disorder, cariprazine in autism, and rare adverse effects of mirtazapine and escitalopram.
Validated assessment tools for clinical research, pharmaceutical trials, and psychiatric practice. Our collection represents decades of rigorous validation trusted by leading research institutions worldwide.
The definitive clinical reference guide for evidence-based psychopharmacology. Authored by Stanford University experts, providing comprehensive dosing guidelines and monitoring protocols.
For over 30 years, MedWorks Media has earned the trust of healthcare professionals worldwide through rigorous editorial standards and prestigious academic partnerships. Our publications are indexed in the world’s most respected medical databases and backed by leading experts from Harvard, Stanford, Columbia, and other premier institutions.
Medical publisher specializing in peer-reviewed journals and clinical resources for healthcare professionals since 1994.
Psychopharmacology Bulletin (ISSN 2472-2448) is indexed in PubMed, SCOPUS, Science Citation Index, and other major medical databases.
© 2026 MedWorks Media Inc. | All Rights Reserved
